Italia markets close in 52 minutes

FTSE MIB
33.591,00
-116,21(-0,34%)
Dow Jones
38.969,71
-142,45(-0,36%)
Nasdaq
17.753,56
+35,90(+0,20%)
Nikkei 225
39.667,07
+493,92(+1,26%)
Petrolio
81,21
+0,38(+0,47%)
Bitcoin EUR
57.704,79
-272,07(-0,47%)

NBIX Jul 2024 140.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

2,2900

-0,0100

(-0,43%)

In data: 03:06PM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat